/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BIOVIE INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.6 0.0816(8.16%) BIVI at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 1.47
Highest Today 1.59
Today’s Open 1.47
Prev. Close 1.47
52 Week High 30.90
52 Week Low 1.25
Day’s Range: Low 1.47 High 1.59
52-Week Range: Low 1.25 High 30.90
1 day return -
1 Week return +7.77
1 month return +3.9
3 month return +1.26
6 month return +47.0
1 year return -42.31
3 year return -69.32
5 year return -81.05
10 year return -

Institutional Holdings

Vanguard Group Inc 0.71

Vanguard Total Stock Mkt Idx Inv 0.62

Geode Capital Management, LLC 0.18

Belfund SICAV Belinvest Equity A USD Acc 0.13

Vanguard Institutional Extnd Mkt Idx Tr 0.11

Fidelity Extended Market Index 0.09

UBS Group AG 0.07

SMH Capital Inc. 0.05

Fidelity Total Market Index 0.03

Fidelity Series Total Market Index 0.03

State Street Corp 0.02

Traynor Capital Management, Inc 0.02

Northern Trust Corp 0.02

Spartan Extended Market Index Pool F 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

Royal Bank of Canada 0.02

Spartan Total Market Index Pool G 0.01

Tower Research Capital LLC 0.01

Morgan Stanley - Brokerage Accounts 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

SBI Securities Co Ltd 0.00

Fidelity Nasdaq Composite Index 0.00

Atlantic Trust Group, LLC 0.00

Northern Trust Extended Eq Market Idx 0.00

Caitong International Asset Management Co., Limited. 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

Spire Wealth Management 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Advisor Group Holdings, Inc. 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

BNYM Mellon SL Market Completion UC1 0.00

Bank of America Corp 0.00

BlackRock Inc 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Steward Partners Investment Advisory, LLC 0.00

Tradewinds Capital Management, LLC 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 11.23 M

PB Ratio 0.4558

PE Ratio 0.0

Enterprise Value -13.29 M

Total Assets 21.56 M

Volume 40991

Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-229377 -0.2M, FY24:-229377 -0.2M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-17542120 -17.5M, FY24:-32120533 -32.1M, FY23:-50255815 -50.3M, FY22:-22797050 -22.8M, FY21:-130808659 -130.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:-57344 -0.1M, Q2/2025:-57344 -0.1M, Q1/2025:-57344 -0.1M, Q4/2024:-57344 -0.1M, Q3/2024:-57344 -0.1M

Quarterly Net worth Q3/2025:-5131101 -5.1M, Q2/2025:-3489141 -3.5M, Q1/2025:-2788418 -2.8M, Q4/2024:-7156953 -7.2M, Q3/2024:-4152032 -4.2M

Fund house & investment objective

Company Information BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Mr. Cuong Viet Do M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow